US 11,701,342 B2
Co-therapies including a metastasis inhibitor
Xin-Yun Huang, New York, NY (US); Jue Jillian Zhang, New York, NY (US); and Christy Young Shue, Towaco, NJ (US)
Assigned to CORNELL UNIVERSITY, Ithaca, NY (US); and NOVITA PHARMACEUTICALS, INC., New York, NY (US)
Appl. No. 16/766,156
Filed by NOVITA PHARMACEUTICALS, INC., New York, NY (US); and CORNELL UNIVERSITY, Ithaca, NY (US)
PCT Filed Nov. 20, 2018, PCT No. PCT/US2018/062069
§ 371(c)(1), (2) Date May 21, 2020,
PCT Pub. No. WO2019/104067, PCT Pub. Date May 31, 2019.
Claims priority of provisional application 62/590,067, filed on Nov. 22, 2017.
Prior Publication US 2020/0352911 A1, Nov. 12, 2020
Int. Cl. A61K 31/4162 (2006.01); A61K 31/337 (2006.01); A61K 31/501 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4162 (2013.01) [A61K 31/337 (2013.01); A61K 31/501 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method of increasing a response to a chemotherapeutic agent or an immunotherapeutic agent in a patient in need thereof, comprising:
administering to the patient a compound A represented by formula:

OG Complex Work Unit Chemistry
or tautomer thereof, and/or a pharmaceutically acceptable salt thereof, wherein the patient is undergoing or about to undergo chemotherapy; and wherein the chemotherapeutic agent is paclitaxel, cyclophosphamide, or doxorubicin.